Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Immupharma files international patent application for P140 precision medicine

Immupharma has filed a PCT application for its P140 approach to identify and treat patients with the so-called type-M immune profile. The application builds on a UK patent (priority Aug/Sep 2025) and includes additional experimental data generated during the 12-month priority period. The international phase includes search and publication and enables the pursuit of national/regional patent rights in selected markets. The company names P140 as a central value driver and aims to conclude a commercial agreement in 2026. » More on de.investing.com
ImmuPharma selects Kymos Group as CRO for Kapiglucagon bioanalysis

ImmuPharma has chosen Kymos Deutschland/Prolytic through a competitive tender as the bioanalytical contract research partner for the Kapiglucagon program. Kymos will develop and validate regulated bioanalytical methods and analyse samples from nonclinical and phase 1 studies. Kapiglucagon is a glucagon prodrug intended for type 1 diabetes applications, aiming to improve solubility and formulation stability for dual-hormone artificial pancreas systems. The program is supported by recently awarded funding; Thermo Fisher is the CMC partner and Bachem is supplying the API, and a US regulatory pathway via 505(b)(2) is being explored. » More on de.investing.com
ImmuPharma starts IND preparations for diabetes prodrug Kapiglucagon

ImmuPharma has initiated IND‑preparatory activities for Kapiglucagon, a glucagon prodrug for treating type 1 diabetes, and has engaged tranScrip Limited to prepare a regulatory strategy and a pre‑IND briefing for the FDA. The company is considering a 505(b)(2) approval pathway in the US, which could allow use of existing data on native glucagon. Kapiglucagon aims to address issues with native glucagon by providing improved solubility and formulation stability and could also be used in artificial pancreas systems. After the pre‑IND meeting, ImmuPharma plans to submit an IND and start first human studies; the program is supported by a recently approved financing initiative. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2021, ImmuPharma has already paid €0.89 in dividends. The last payout was in December 2021.

Financials

In the last quarter, ImmuPharma had revenue of €0 and net profit of -€5.46m

(EUR)	June 2026	YoY
Revenue	0	-
Gross profit	-576.92	98.26%
Net profit	-5.46m	409.81%
EBITDA	-1.24m	77.13%

Fundamentals

Metric	Value
Market capitalization	€24.28m
Number of shares	623.91m
52-week high/low	€0.14 - €0.0362
Dividends	No
Beta	3.02
P/E ratio	-2.60
PEG ratio	0.02
P/B ratio	9.97
P/S ratio	0.00

Company profile

ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease. Its other product candidates include BioAMB, a peptide-based drug for the treatment of Amphotericin-B formulations, a fungal infection caused by the aspergillus family of fungi; and BioCin, a peptide-based antibacterial drug used in high medical need cases and in last line of defense. The company has a collaboration arrangement with Centre National de la Recherche Scientifique for the development of a peptide technology platform for treating diabetes with glucagon-like peptide -1 agonists, as well as development of peptides as glucagon antagonists to treat type I and type II diabetes; and license and development agreement with Avion Pharmaceuticals LLC. ImmuPharma plc was founded in 1999 and is headquartered in London, the United Kingdom.